title: Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
authors.affiliation: Mayo Clinic, Rochester, MN 55905.
authors.forename: M K
authors.initials: MK
authors.lastname: Porayko
authors.forename: S C
authors.initials: SC
authors.lastname: Textor
authors.forename: R A
authors.initials: RA
authors.lastname: Krom
authors.forename: J E
authors.initials: JE
authors.lastname: Hay
authors.forename: G J
authors.initials: GJ
authors.lastname: Gores
authors.forename: H E
authors.initials: HE
authors.lastname: Wahlstrom
authors.forename: L
authors.initials: L
authors.lastname: Sanchez-Urdazpal
authors.forename: T
authors.initials: T
authors.lastname: Richards
authors.forename: P
authors.initials: P
authors.lastname: Crotty
authors.forename: S
authors.initials: S
authors.lastname: Beaver
mesh_terms: D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use / Q000633:toxicity*; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use / Q000633:toxicity*
chemical_list: D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus